Fig. 5
Plasma-derived EV characterization and effects on the survival of MF- or CB-derived CD34+ cells. a NTA size distribution profiles of the EVs collected from plasma of HD (n = 12), JAK2V617F-mutated (n = 13) and TN patients (n = 6). b Frequency of MK‐EVs (CD61+/CD62P‐; c PLT‐EVs (CD61+/CD62P+, d and Mitotracker-EVs (CD61+/Mito+); from HD (black, n = 3), JAK2V617F-mutated (grey, n = 3) or TN (blue, n = 3) patients. Accordingly, the MitoTracker Red CMXRos MFI in the same samples (e). f Survival rate as fold-change of cord blood-, JAK2V617F-, TN-derived CD34+ co-cultured with EVs isolated from plasma of HD (black, n=3), JAK2V617F-mutated (grey, n=3) or TN (blue, n = 3). Results are expressed as mean percentages ± SEM (*p ≤ 0.05; **p ≤ 0.01). CB: cord blood